25.28
-0.29 (-1.13%)
| 前收盘价格 | 25.57 |
| 收盘价格 | 25.47 |
| 成交量 | 1,947,584 |
| 平均成交量 (3个月) | 2,390,107 |
| 市值 | 4,034,583,040 |
| 价格/销量 (P/S) | 14.05 |
| 股市价格/股市净资产 (P/B) | 31.15 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2026 |
| 营业毛利率 | -74.84% |
| 营业利益率 (TTM) | -56.45% |
| 稀释每股收益 (EPS TTM) | -0.950 |
| 季度收入增长率 (YOY) | 25.20% |
| 总债务/股东权益 (D/E MRQ) | 115.90% |
| 流动比率 (MRQ) | 2.92 |
| 营业现金流 (OCF TTM) | -85.34 M |
| 杠杆自由现金流 (LFCF TTM) | -21.40 M |
| 资产报酬率 (ROA TTM) | -15.05% |
| 股东权益报酬率 (ROE TTM) | -61.03% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 看涨 |
| Diagnostics & Research (全球的) | 混合的 | 看涨 | |
| 股票 | Adaptive Biotechnologies Corpor | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -3.5 |
| 价格波动 | -3.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | -1.25 |
|
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Core |
| 内部持股比例 | 2.35% |
| 机构持股比例 | 98.36% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BOBULSKY SUSAN | - | 26.90 | -6,444 | -173,344 |
| RUBINSTEIN JULIE | - | 27.49 | -59,405 | -1,633,162 |
| 累积净数量 | -65,849 | |||
| 累积净值 ($) | -1,806,506 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 27.39 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| RUBINSTEIN JULIE | 职员 | 08 Oct 2026 | 自动卖出 (-) | 11,881 | 26.09 | 309,975 |
| RUBINSTEIN JULIE | 职员 | 08 Oct 2026 | 执行期权 | 11,881 | - | - |
| RUBINSTEIN JULIE | 职员 | 07 Oct 2026 | 自动卖出 (-) | 11,881 | 26.28 | 312,233 |
| RUBINSTEIN JULIE | 职员 | 07 Oct 2026 | 执行期权 | 11,881 | - | - |
| BOBULSKY SUSAN | 职员 | 06 Oct 2026 | 自动卖出 (-) | 6,444 | 26.90 | 173,344 |
| RUBINSTEIN JULIE | 职员 | 06 Oct 2026 | 自动卖出 (-) | 11,881 | 26.90 | 319,599 |
| RUBINSTEIN JULIE | 职员 | 06 Oct 2026 | 执行期权 | 11,881 | - | - |
| RUBINSTEIN JULIE | 职员 | 05 Oct 2026 | 自动卖出 (-) | 11,881 | 29.84 | 354,529 |
| RUBINSTEIN JULIE | 职员 | 05 Oct 2026 | 执行期权 | 11,881 | - | - |
| RUBINSTEIN JULIE | 职员 | 02 Oct 2026 | 自动卖出 (-) | 11,881 | 28.35 | 336,826 |
| RUBINSTEIN JULIE | 职员 | 02 Oct 2026 | 执行期权 | 11,881 | - | - |
| 显示更多 | ||||||
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合